Pharvaris N.V. (PHVS)
Nasdaq · Healthcare · Biotechnology
$30.49−2.24%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.1B
- 52-week range
- $20.65 – $43.25
- 52-week change
- +34.15%
- EPS (trailing)
- −$3.06
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 12, 2026
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Headquarters: Zug, Switzerland · 148 employees · pharvaris.com